Pharma & Healthcare

Global Disease-Modifying Antirheumatic Drug Market Research Report 2024

It refers to drugs that can treat rheumatism, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, etc.
The global Disease-Modifying Antirheumatic Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Disease-Modifying Antirheumatic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Disease-Modifying Antirheumatic Drug.
Report Scope
The Disease-Modifying Antirheumatic Drug market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Disease-Modifying Antirheumatic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Disease-Modifying Antirheumatic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Amgen
Pfizer
Roche Holding AG
Novartis International AG
Johnson & Johnson
Bristol-Myers Squibb
Merck
UCB S.A.
Eli Lilly and Company
Segment by Type
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation
Segment by Application
Pharmaceutical Industry
Hospital and Clinic
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Disease-Modifying Antirheumatic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Disease-Modifying Antirheumatic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Disease-Modifying Antirheumatic Drug Market Overview
1.1 Product Overview and Scope of Disease-Modifying Antirheumatic Drug
1.2 Disease-Modifying Antirheumatic Drug Segment by Type
1.2.1 Global Disease-Modifying Antirheumatic Drug Market Value Comparison by Type (2024-2030)
1.2.2 Non-Steroidal Anti-Inflammatory Drugs
1.2.3 Steroidal Anti-Inflammatory Drugs
1.2.4 Slow Acting Drug
1.2.5 Immunological Preparation
1.3 Disease-Modifying Antirheumatic Drug Segment by Application
1.3.1 Global Disease-Modifying Antirheumatic Drug Market Value by Application: (2024-2030)
1.3.2 Pharmaceutical Industry
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Global Disease-Modifying Antirheumatic Drug Market Size Estimates and Forecasts
1.4.1 Global Disease-Modifying Antirheumatic Drug Revenue 2019-2030
1.4.2 Global Disease-Modifying Antirheumatic Drug Sales 2019-2030
1.4.3 Global Disease-Modifying Antirheumatic Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Disease-Modifying Antirheumatic Drug Market Competition by Manufacturers
2.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Disease-Modifying Antirheumatic Drug Average Price by Manufacturers (2019-2024)
2.4 Global Disease-Modifying Antirheumatic Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Product Type & Application
2.7 Disease-Modifying Antirheumatic Drug Market Competitive Situation and Trends
2.7.1 Disease-Modifying Antirheumatic Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Disease-Modifying Antirheumatic Drug Players Market Share by Revenue
2.7.3 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Disease-Modifying Antirheumatic Drug Retrospective Market Scenario by Region
3.1 Global Disease-Modifying Antirheumatic Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Disease-Modifying Antirheumatic Drug Global Disease-Modifying Antirheumatic Drug Sales by Region: 2019-2030
3.2.1 Global Disease-Modifying Antirheumatic Drug Sales by Region: 2019-2024
3.2.2 Global Disease-Modifying Antirheumatic Drug Sales by Region: 2025-2030
3.3 Global Disease-Modifying Antirheumatic Drug Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2019-2030
3.3.1 Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2019-2024
3.3.2 Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2025-2030
3.4 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.4.1 North America Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.4.3 North America Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.5.1 Europe Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.5.3 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.7.1 Latin America Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.7.3 Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2019-2030)
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024)
4.1.2 Global Disease-Modifying Antirheumatic Drug Sales by Type (2025-2030)
4.1.3 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2030)
4.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2019-2030)
4.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2019-2024)
4.2.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2025-2030)
4.2.3 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2030)
4.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Disease-Modifying Antirheumatic Drug Sales by Application (2019-2030)
5.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024)
5.1.2 Global Disease-Modifying Antirheumatic Drug Sales by Application (2025-2030)
5.1.3 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2030)
5.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2019-2030)
5.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2019-2024)
5.2.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2025-2030)
5.2.3 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2019-2030)
5.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AbbVie Disease-Modifying Antirheumatic Drug Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Disease-Modifying Antirheumatic Drug Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Disease-Modifying Antirheumatic Drug Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Roche Holding AG
6.4.1 Roche Holding AG Corporation Information
6.4.2 Roche Holding AG Description and Business Overview
6.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Product Portfolio
6.4.5 Roche Holding AG Recent Developments/Updates
6.5 Novartis International AG
6.5.1 Novartis International AG Corporation Information
6.5.2 Novartis International AG Description and Business Overview
6.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Product Portfolio
6.5.5 Novartis International AG Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck Disease-Modifying Antirheumatic Drug Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 UCB S.A.
6.9.1 UCB S.A. Corporation Information
6.9.2 UCB S.A. Description and Business Overview
6.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Product Portfolio
6.9.5 UCB S.A. Recent Developments/Updates
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Corporation Information
6.10.2 Eli Lilly and Company Description and Business Overview
6.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Portfolio
6.10.5 Eli Lilly and Company Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Disease-Modifying Antirheumatic Drug Industry Chain Analysis
7.2 Disease-Modifying Antirheumatic Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Disease-Modifying Antirheumatic Drug Production Mode & Process
7.4 Disease-Modifying Antirheumatic Drug Sales and Marketing
7.4.1 Disease-Modifying Antirheumatic Drug Sales Channels
7.4.2 Disease-Modifying Antirheumatic Drug Distributors
7.5 Disease-Modifying Antirheumatic Drug Customers
8 Disease-Modifying Antirheumatic Drug Market Dynamics
8.1 Disease-Modifying Antirheumatic Drug Industry Trends
8.2 Disease-Modifying Antirheumatic Drug Market Drivers
8.3 Disease-Modifying Antirheumatic Drug Market Challenges
8.4 Disease-Modifying Antirheumatic Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Disease-Modifying Antirheumatic Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Disease-Modifying Antirheumatic Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Disease-Modifying Antirheumatic Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Disease-Modifying Antirheumatic Drug Sales (MT) of Key Manufacturers (2019-2024)
Table 5. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Disease-Modifying Antirheumatic Drug Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Disease-Modifying Antirheumatic Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Product Type & Application
Table 12. Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Disease-Modifying Antirheumatic Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Disease-Modifying Antirheumatic Drug Sales by Region (2019-2024) & (MT)
Table 18. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2019-2024)
Table 19. Global Disease-Modifying Antirheumatic Drug Sales by Region (2025-2030) & (MT)
Table 20. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2025-2030)
Table 21. Global Disease-Modifying Antirheumatic Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Disease-Modifying Antirheumatic Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Disease-Modifying Antirheumatic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 27. North America Disease-Modifying Antirheumatic Drug Sales by Country (2025-2030) & (MT)
Table 28. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Disease-Modifying Antirheumatic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 32. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2025-2030) & (MT)
Table 33. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2019-2024) & (MT)
Table 37. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2025-2030) & (MT)
Table 38. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Disease-Modifying Antirheumatic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 42. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2025-2030) & (MT)
Table 43. Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2024) & (MT)
Table 47. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales by Country (2025-2030) & (MT)
Table 48. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2019-2024)
Table 51. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2025-2030)
Table 52. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2024)
Table 53. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2025-2030)
Table 54. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Type (2019-2024)
Table 59. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Type (2025-2030)
Table 60. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2019-2024)
Table 61. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2025-2030)
Table 62. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2024)
Table 63. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2025-2030)
Table 64. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Application (2019-2024)
Table 69. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Application (2025-2030)
Table 70. AbbVie Corporation Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 73. AbbVie Disease-Modifying Antirheumatic Drug Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Amgen Corporation Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 78. Amgen Disease-Modifying Antirheumatic Drug Product
Table 79. Amgen Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 83. Pfizer Disease-Modifying Antirheumatic Drug Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Roche Holding AG Corporation Information
Table 86. Roche Holding AG Description and Business Overview
Table 87. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 88. Roche Holding AG Disease-Modifying Antirheumatic Drug Product
Table 89. Roche Holding AG Recent Developments/Updates
Table 90. Novartis International AG Corporation Information
Table 91. Novartis International AG Description and Business Overview
Table 92. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 93. Novartis International AG Disease-Modifying Antirheumatic Drug Product
Table 94. Novartis International AG Recent Developments/Updates
Table 95. Johnson & Johnson Corporation Information
Table 96. Johnson & Johnson Description and Business Overview
Table 97. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 98. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product
Table 99. Johnson & Johnson Recent Developments/Updates
Table 100. Bristol-Myers Squibb Corporation Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 103. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product
Table 104. Bristol-Myers Squibb Recent Developments/Updates
Table 105. Merck Corporation Information
Table 106. Merck Description and Business Overview
Table 107. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 108. Merck Disease-Modifying Antirheumatic Drug Product
Table 109. Merck Recent Developments/Updates
Table 110. UCB S.A. Corporation Information
Table 111. UCB S.A. Description and Business Overview
Table 112. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 113. UCB S.A. Disease-Modifying Antirheumatic Drug Product
Table 114. UCB S.A. Recent Developments/Updates
Table 115. Eli Lilly and Company Corporation Information
Table 116. Eli Lilly and Company Description and Business Overview
Table 117. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 118. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product
Table 119. Eli Lilly and Company Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Disease-Modifying Antirheumatic Drug Distributors List
Table 123. Disease-Modifying Antirheumatic Drug Customers List
Table 124. Disease-Modifying Antirheumatic Drug Market Trends
Table 125. Disease-Modifying Antirheumatic Drug Market Drivers
Table 126. Disease-Modifying Antirheumatic Drug Market Challenges
Table 127. Disease-Modifying Antirheumatic Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Disease-Modifying Antirheumatic Drug
Figure 2. Global Disease-Modifying Antirheumatic Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Disease-Modifying Antirheumatic Drug Market Share by Type in 2023 & 2030
Figure 4. Non-Steroidal Anti-Inflammatory Drugs Product Picture
Figure 5. Steroidal Anti-Inflammatory Drugs Product Picture
Figure 6. Slow Acting Drug Product Picture
Figure 7. Immunological Preparation Product Picture
Figure 8. Global Disease-Modifying Antirheumatic Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Disease-Modifying Antirheumatic Drug Market Share by Application in 2023 & 2030
Figure 10. Pharmaceutical Industry
Figure 11. Hospital and Clinic
Figure 12. Other
Figure 13. Global Disease-Modifying Antirheumatic Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Disease-Modifying Antirheumatic Drug Market Size (2019-2030) & (US$ Million)
Figure 15. Global Disease-Modifying Antirheumatic Drug Sales (2019-2030) & (MT)
Figure 16. Global Disease-Modifying Antirheumatic Drug Average Price (USD/MT) & (2019-2030)
Figure 17. Disease-Modifying Antirheumatic Drug Report Years Considered
Figure 18. Disease-Modifying Antirheumatic Drug Sales Share by Manufacturers in 2023
Figure 19. Global Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Disease-Modifying Antirheumatic Drug Players: Market Share by Revenue in 2023
Figure 21. Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Disease-Modifying Antirheumatic Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2030)
Figure 24. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2030)
Figure 28. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2030)
Figure 29. Germany Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2019-2030)
Figure 36. China Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2030)
Figure 47. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. U.A.E Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Disease-Modifying Antirheumatic Drug by Type (2019-2030)
Figure 57. Global Revenue Market Share of Disease-Modifying Antirheumatic Drug by Type (2019-2030)
Figure 58. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Type (2019-2030)
Figure 59. Global Sales Market Share of Disease-Modifying Antirheumatic Drug by Application (2019-2030)
Figure 60. Global Revenue Market Share of Disease-Modifying Antirheumatic Drug by Application (2019-2030)
Figure 61. Global Disease-Modifying Antirheumatic Drug Price (USD/MT) by Application (2019-2030)
Figure 62. Disease-Modifying Antirheumatic Drug Value Chain
Figure 63. Disease-Modifying Antirheumatic Drug Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies